Legacy Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Legacy Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-58	Closed	-$8K	–	443
2017 Q3	$8K	Buy	+58	New	+$7.88K	0.01%	246

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Legacy Advisors's ALXN Position: Q4 2017 in Review

Legacy Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 58 shares — an estimated $8K sold.

Legacy Advisors first reported a position in ALXN in Q3 2017 and held it in 1 quarter. The position peaked at $8K in Q3 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

Legacy Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Legacy Advisors sold 58 Alexion Pharmaceuticals shares in Q4 2017, an estimated $8K.
Legacy Advisors first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 1 quarter.
Legacy Advisors's Alexion Pharmaceuticals position peaked at $8K in Q3 2017.
587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Legacy Advisors's 13F filing for Q4 2017, filed 26 Jan 2018.